NCT02977689View on ClinicalTrials.gov

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2018

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Glioma
Interventions
DRUG

IDH305

study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.

Trial Locations (1)

10016

Laura & Isaac Perlmutter Cancer Center & NYU Langone Medical Center, New York

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

NYU Langone Health

OTHER

NCT02977689 - Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | Biotech Hunter | Biotech Hunter